Company research
AVADEL PHARMACEUTICALS PLC
CIK 1012477Updated Sep 27, 2026
Securities
Historical securities (1)
AVDL · NASDAQ · equity · closed Feb 12, 2026Name history
FLAMEL TECHNOLOGIES SA · through Dec 30, 2016
AVDL price & chart
Historical security
This listing closed Feb 12, 2026. Live provider charts are shown only for current listings.
About the company
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Avadel’s approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration as the first and only once-at-bedtime oxybate for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit Avadel’s website at www.avadel.com.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 164,236,000Source | 164,698,000Source | 132,785,000Source | 247,265,000Source |
| Property, Plant and Equipment, NetUSD | 453,000Source | 585,000Source | 839,000Source | 285,000Source |
| GoodwillUSD | 16,836,000Source | 16,836,000Source | 16,836,000Source | 16,836,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 51,371,000Source | 31,167,000Source | 73,981,000Source | 50,708,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 34,097,000Source | 12,103,000Source | — | — |
| Inventory, NetUSD | 20,298,000Source | 10,380,000Source | — | — |
| Assets, CurrentUSD | 134,208,000Source | 134,202,000Source | 100,843,000Source | 192,490,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,036,000Source | 5,286,000Source | 2,096,000Source | 32,826,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,702,000Source | 2,591,000Source | 1,713,000Source | 2,652,000Source |
| Other Assets, NoncurrentUSD | 11,037,000Source | 10,152,000Source | 11,322,000Source | 33,777,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 90,388,000Source | 76,959,000Source | 153,930,000Source | 169,021,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 52,000Source | 5,000Source | 5,000Source |
| Common Stock, Value, IssuedUSD | 965,000Source | 898,000Source | 628,000Source | 586,000Source |
| Retained Earnings (Accumulated Deficit)USD | -794,328,000Source | -745,496,000Source | -585,220,000Source | -447,756,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -24,580,000Source | -23,167,000Source | -26,341,000Source | -23,940,000Source |
| Stockholders' Equity Attributable to ParentUSD | 73,848,000Source | 87,739,000Source | -21,145,000Source | 78,244,000Source |
| Additional Paid in Capital, Common StockUSD | 891,791,000Source | 855,452,000Source | 589,783,000Source | 549,349,000Source |
| Liabilities and EquityUSD | 164,236,000Source | 164,698,000Source | 132,785,000Source | 247,265,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 48,834,000Source | 36,855,000Source | 55,793,000Source | 21,000,000Source |
| Operating Lease, Liability, CurrentUSD | 582,000Source | 934,000Source | 960,000Source | 900,000Source |
| Accounts Payable, CurrentUSD | 7,328,000Source | 11,433,000Source | 7,890,000Source | 7,679,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,122,000Source | 1,690,000Source | 780,000Source | 1,707,000Source |
| Other Liabilities, NoncurrentUSD | 5,183,000Source | 5,654,000Source | 5,743,000Source | 3,917,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 40,651,000Source | 24,227,000Source | 7,334,000Source | 7,151,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 37,668,000Source | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 91,614,000Source | 142,397,000Source |
| Short-term InvestmentsUSD | — | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 20,387,000Source | 15,811,000Source | 7,013,000Source | 8,872,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 21,994,000Source | 12,103,000Source | — | 0Source |
| Increase (Decrease) in InventoriesUSD | 9,219,000Source | 9,532,000Source | — | 0Source |
| Increase (Decrease) in Accounts PayableUSD | -4,093,000Source | 1,545,000Source | -3,108,000Source | 4,232,000Source |
| Deferred Income Tax Expense (Benefit)USD | -247,000Source | 160,000Source | 26,025,000Source | -15,876,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -46,907,000Source | -128,511,000Source | -70,304,000Source | -77,310,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 51,780,000Source | -50,093,000Source | 79,698,000Source | 56,929,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 0Source | 716,000Source | 26,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 15,970,000Source | 135,335,000Source | 14,543,000Source | 263,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 20,204,000Source | -42,814,000Source | 23,273,000Source | -21,014,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 51,371,000Source | 31,167,000Source | 73,981,000Source | 50,708,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 7,181,000Source | 5,250,000Source | 9,660,000Source | 6,469,000Source |
| Income Taxes Paid, NetUSD | 0Source | 0Source | -29,058,000Source | 76,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -639,000Source | 455,000Source | -664,000Source | -896,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 20,388,000Source | 15,811,000Source | 7,013,000Source | 8,872,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 0Source | 2,796,000Source | 6,052,000Source | 1,248,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | 0Source |
| Deconsolidation, Gain (Loss), AmountUSD | — | — | — | 0Source |
| Deconsolidation, Revaluation of Retained Investment, Gain (Loss), AmountUSD | — | — | — | 217,000Source |
| DepreciationUSD | 132,000Source | 254,000Source | 162,000Source | 97,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -13,129,000Source | 203,000Source | — |
| GoodwillUSD | 16,836,000Source | 16,836,000Source | 16,836,000Source | 16,836,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | -247,000Source | -501,000Source | 26,025,000Source | -15,816,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,832,000Source | -160,276,000Source | -137,464,000Source | -77,329,000Source |
| Operating ExpensesUSD | 196,239,000Source | 164,966,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | 25,318,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 30,000,000Source | — | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 169,117,000Source | 27,963,000Source | 0Source | 0Source |
| Cost of RevenueUSD | 15,277,000Source | 846,000Source | — | 0Source |
| Selling, General and Administrative ExpenseUSD | 181,043,000Source | 151,705,000Source | 74,516,000Source | 68,495,000Source |
| Operating Income (Loss)USD | -42,399,000Source | -137,849,000Source | -98,561,000Source | -85,546,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -49,079,000Source | -160,777,000Source | -111,439,000Source | -93,145,000Source |
| Income Tax Expense (Benefit)USD | -247,000Source | -501,000Source | 26,025,000Source | -15,816,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,832,000Source | -160,276,000Source | -137,464,000Source | -77,329,000Source |
| Earnings Per Share, BasicUSD per share | -0.51Source | -2Source | -2.29Source | -1.32Source |
| Earnings Per Share, DilutedUSD per share | -0.51Source | -2Source | -2.29Source | -1.32Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 95,141,000Source | 80,174,000Source | 60,094,000Source | 58,535,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 95,141,000Source | 80,174,000Source | 60,094,000Source | 58,535,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | — | 0Source |
| Business Combination, Acquisition Related CostsUSD | — | — | — | 0Source |
| Costs and ExpensesUSD | — | — | 98,561,000Source | 85,546,000Source |
| Current Income Tax Expense (Benefit)USD | 0Source | -661,000Source | 0Source | 60,000Source |
| Deconsolidation, Revaluation of Retained Investment, Gain (Loss), AmountUSD | — | — | — | 217,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,681,000Source | 1,766,000Source | 1,493,000Source | 815,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 153,840,000Source | 27,117,000Source | — | — |
| Interest ExpenseUSD | — | — | 12,342,000Source | 9,942,000Source |
| Interest Expense, DebtUSD | 10,830,000Source | 9,886,000Source | 12,342,000Source | 9,942,000Source |
| Investment Income, NetUSD | 4,150,000Source | 87,000Source | -536,000Source | 2,126,000Source |
| Operating ExpensesUSD | 196,239,000Source | 164,966,000Source | — | — |
| Research and Development ExpenseUSD | 15,196,000Source | 13,261,000Source | 20,700,000Source | 17,104,000Source |
Filing attachments
tm265930d1_ex99-1.htm · 8-K · 2026-02-12
EX-99.1 3 tm265930d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - Augments Alkermes’ Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ® (Sodium Oxybate) for Extended-Release Oral Suspension - - Expected to be Accretive in 202…
Read attachment ↗tm262904d1_ex99-1.htm · 8-K · 2026-01-12
EX-99.1 2 tm262904d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. [FOR IMMEDIATE RELEASE] Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes DUBLIN, January 12, 2026 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporate…
Read attachment ↗tm2533819d1_ex99-1.htm · 8-K · 2025-12-18
EX-99.1 2 tm2533819d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia - Data expected in Q2 2026 - DUBLIN, December 18, 2025 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM (sodium oxybate) extended-release oral susp…
Read attachment ↗tm2529228d13_ex99-1.htm · 8-K · 2025-11-19
EX-99.1 3 tm2529228d13_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, November 19, 2025 - Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced that the com…
Read attachment ↗tm2531449d1_ex99-1.htm · 8-K · 2025-11-17
EX-99.1 2 tm2531449d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE …
Read attachment ↗tm2529228d9_ex99-1.htm · 8-K · 2025-11-14
EX-99.1 2 tm2529228d9_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE …
Read attachment ↗